Close menu

January 10th, 2022 | 12:02 CET

Trading stocks in focus: Aspermont, BASF, BioNTech

  • Trading
Photo credits:

At the beginning of the week, the DAX is currently trading around 0.19% down at 15,939 points and thus remains below the psychological mark of 16,000 points. The MDAX recently traded again below the 35,000 mark at 34,804 points (-0.52%), TexDAX at 3,653 points (-1.50%) and SDAX at 15,936 points with 1.06% in the red. Overall, the indices had given back their initial gains from the start of trading and are trading in negative territory in the morning.

time to read: 1 minutes | Author: Mario Hose

Table of contents:

    Most traded companies

    The share of BioNTech is currently with over 2,000 trades at the level of 188.00 EUR and a change of +0.99% on Tradegate the most frequently traded stock. The BASF share comes to over 1,100 trades and is thus at the DAX top of the most traded companies. The value of the chemical giant's stock loses about 0.09% to EUR 66.03.

    Announcement of the company raises interest

    Aspermont's stock is up 11.4% today and last traded at EUR 0.0156. The B2B media market leader with a home exchange in Australia is in the focus of investors today, as a corporate announcement reported a collaboration with Asian investment advisory firm Soochow CSSD Capital Markets. Under the collaboration, Soochow has the option to purchase up to 250 million shares at a price of AUD 0.0432 until the end of September 2022. The collaboration is performance-based with the stock options. The shares closed at AUD 0.025 on the ASX, the company's home exchange, today.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Mario Hose

    Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

    About the author

    Related comments:

    Commented by Mario Hose on January 13th, 2022 | 12:01 CET

    Stocks offer trading opportunities: BrainChip, TeamViewer, XPhyto

    • Trading

    On Thursday, most German indices started trading with negative signs. The DAX is currently trading at 15,989 points, down around 0.25%. The psychological mark of 16,000 points has not held compared to the previous day. The MDAX last traded at 34,874 points (-0.14%), TecDAX at 3,637 points (-0.62%) and SDAX at 16,062 points with 0.13% in the red. In the single stocks, on the other hand, there are exciting developments for the stock traders.


    Commented by Mario Hose on January 11th, 2022 | 11:36 CET

    Trading stocks in focus: BioNTech, Darktrace, EXMceuticals

    • Trading

    Tuesday is under a good omen on the stock market after a failed start to the week. Germany's leading index, the DAX, is trading at 15,961 points, up around 0.32%, but has not yet made it above the psychological 16,000 mark. The MDAX last traded at 34,713 points (+0.42%), TexDAX at 3,661 points (+1.09%) and SDAX at 15,913 points with 0.66% in the plus.


    Commented by Mario Hose on January 7th, 2022 | 16:04 CET

    Trading shares in focus: Allianz, BioNTech, BrainChip

    • Trading

    At the end of the week, the DAX was down around 0.37% at 15,968 points and thus below the psychological mark of 16,000 points. The MDAX last traded at 35,002 points (-34%), TexDAX at 3,731 points (-0.36%) and SDAX at 16,125 points with 0.92% in the red.